This analysis demonstrates high in vivo stability of hydrogel implants in mice, indicating therapeutic applications for safe biomaterials.
Nanofibrillar cellulose (NFC) hydrogel has emerged as a promising implantable material for therapeutic applications. In this study, the relatively longer-lived positron-emitting radionuclide zirconium-89 was chelated to the octadentate deferoxamine (DFO*)-conjugated NFC hydrogel ([⁸⁹Zr]Zr-DFO*-NFC) to enable longitudinal monitoring of its in vivo fate using positron emission tomography techniques. Following subcutaneous implantation in healthy mice, [⁸⁹Zr]Zr-DFO*-NFC retained radioactivity at the implant site for at least 14 days, with minimal signal detected in the kidneys, urinary bladder, and overlying skin. In contrast, mice receiving a control formulation of [⁸⁹Zr]Zr-oxalate mixed with NFC hydrogel showed progressive accumulation of radioactivity in the bones, consistent with known [⁸⁹Zr]Zr-oxalate distribution patterns, and only limited retention at the implant site by Day 7. These findings demonstrate that [⁸⁹Zr]Zr-DFO*-NFC hydrogel implants exhibit high in vivo stability with negligible systemic release following subcutaneous implantation, supporting their potential use as safe and traceable biomaterial platforms.
No takes yet. Share an insight, caveat, or question.
Zhuang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: